ARTICLE | Clinical News
GH9001: Began Phase I trial
December 24, 2001 8:00 AM UTC
GlycoDesign Inc. (TSE:GD), Toronto, Ontario Leo Pharmaceutical Products Ltd., Ballerup, Denmark Product: GH9001 Business: Cardiovascular Therapeutic category: Thrombosis/Thrombolysis Target: Thrombi...